Veredus Laboratories Pte Ltd (“Veredus”) announced today the launch of its Extraction-free RT-PCR Suite consisting of VereRT™ COVID-19 PCR Kit (formerly known as VereRTCoV™ SARSCoV-2 Real-Time RT-PCR 2.0) for direct use either on human saliva (ZeroPrep™ Saliva Collection Kit, formerly known as VereRTCoV™ ZeroStep Saliva Collection Kit) or from swab (ZeroPrep™ Swab Buffer Kit).
Saliva Test – ZeroPrep™ Saliva Collection Kit, when used in conjuction with VereRT™ COVID-19 PCR Kit, is intended for direct testing on human saliva for COVID-19 diagnosis. This specimen collection method is non-invasive as saliva can be obtained easily without assistance as compared to nasopharyngeal swab where trained medical personnel is required to perform the swabbing procedure. This reduces manpower and eliminates their exposure to the virus. ZeroPrep™ Saliva Collection Kit is able to collect human saliva as a specimen for COVID-19 diagnosis as it has a specially formulated preservation buffer to stablise and preserve viral RNA, enabling it to be used directly in the PCR test without the need for nucleic acid extraction as an intermediate step.
Swab Test – The current prevalent COVID-19 screening regime relies heavily on nasopharyngeal swab test, where the specimen is obtained and deposited in transport media before being sent to the testing laboratory. Upon receiving the specimen, the initial step of molecular diagnosis is to extract the genetic material from the virus followed by DNA amplification to identify SARS-CoV-2 responsible for COVID-19.
VereRT™ COVID-19 PCR Kit, when used in conjunction with ZeroPrep™ Swab Buffer Kit, is a next generation PCR-based In Vitro Diagnostic (“IVD”) test for COVID-19. It shortcuts the testing workflow by eliminating the nucleic acid extraction process as the operator is able to perform the diagnostic test directly from the swab. By eliminating the extraction phase which comprises of several laborious steps, it results in cost- and timesaving, as well as a reduction in vulnerability to supply chain shortages especially during high-volume testing by laboratories globally.
VereRT™ COVID-19 PCR Kit has obtained CE-IVD marking and Provisional Authorization from Health Sciences Authority (HSA) Singapore for use as an IVD test for supply to hospitals and medical clinics for use on patients to diagnose COVID-19 in Singapore.
“Veredus is innovating rapidly and we are excited to be one of few companies offering direct PCR testing using saliva or swab without the need for viral RNA extraction. This method of direct COVID-19 testing is the next step for us as we seek to increase the testing capacity of healthcare authorities and laboratories by reducing workflow complexity in COVID-19 molecular testing.” said Dr. Rosemary Tan, Chief Executive Officer of Veredus Laboratories.
Veredus Laboratories Pte Ltd “Veredus” has received CE-IVD marking for VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 as a molecular diagnostic test kit to be used in clinical practice across Europe and other countries that recognize the CE Mark. This announcement follows the recent commercial launch of this IVD test with approvals from Health Sciences Authority (HSA) Singapore and Philippines FDA.
VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 is a one-step Reverse Transcription Polymerase Chain Reaction (RT-PCR)-based IVD test intended for the qualitative detection of nucleic acid belonging to SARS-CoV-2.
“We are very pleased with the European launch of our test and for Veredus to reach out beyond South East Asia and into the European region to support countries in need for molecular test to detect and identify the SARS-CoV-2 virus. At the same time, with this CE-IVD marking, we can now plan for immediate rollout to healthcare institutions around the world for diagnostic use. Veredus is commited to join the fight against COVID-19 and will continue to help move precision testing forward,” said Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.
Veredus Laboratories Pte Ltd “Veredus” announced today that it has received Provisional Authorisation from Singapore Health Sciences Authority (HSA) for LIONRUN Diagnostic Kit for Antibody IgM/IgG of Novel Coronavirus COVID-19 “LIONRUN Antibody Kit”. Veredus can supply to the healthcare institutions, private hospitals, medical clinics or clinical laboratories licensed under the PHMC Act (Cap. 248) for use on their patients.
LIONRUN Antibody Kit is a colloidal gold IgM/IgG immunochromatography antibody test and is intended for the qualitative and differential detection of IgM and IgG antibodies against the 2019 novel Coronavirus (2019-nCoV) also known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in human whole blood, serum or plasma, capable of providing test results in 10 minutes. LIONRUN Antibody Kit is a product manufactured by Shanghai LiangRun Biomedicine Technology Co. Ltd.
Dr Rosemary Tan, CEO of Veredus Laboratories said “We are proud to receive this Provisional Authorisation for LIONRUN Antibody Kit to be used directly on patients in Singapore as an alternative to molecular laboratory testing. This lays a path for clinical testing to be performed outside a central laboratory where local communities can be screened at frontline and triage centers in a time- and cost-effective manner.”
Veredus Laboratories Pte Ltd “Veredus” today announced the CE-IVD marking of VereCoV™ Detection Kit for commercial launch in Europe. The test is intended for the qualitative detection of 2019 novel Coronavirus (2019-nCoV) also known as SARSCoV- 2 that causes COVID-19.
The kit was developed to provide an easy-to-use solution for clinical testing, public health surveillance and detection of the coronavirus from nasal or nasopharyngeal swab specimen to enable authorities to take appropriate actions. The test integrates PCR amplification and microarray for rapid qualitative detection of 2019-nCoV with the additional capability to detect a subset of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) simultaneously with the same test.
“We are ready to respond effectively to the needs of hospitals and reference laboratories by providing a quality molecular testing solution for the pandemic,” says Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.
Veredus Laboratories Pte Ltd “Veredus” has obtained the Provisional Authorisation from Singapore Health Sciences Authority (HSA) for its VereCoV™ Detection Kit following Veredus’ rapid launch of this kit as a “Research Use Only” (RUO) test earlier this year. With this Authorisation, VereCoV™ Detection Kit can be used directly by laboratories or hospitals to test patients for clinical diagnosis.
Veredus Laboratories Pte Ltd “Veredus”, a leading provider of innovative molecular diagnostic solutions, announced today the development of VereCoV detection kit, a portable Lab-on-Chip application capable of detecting the Middle-East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and 2019 Novel Coronavirus (2019-nCoV) i.e. Wuhan Coronavirus, in a single test.
VereBeef™ Detection Kit used in conjunction with the VerePLEX™ Biosystem is best described as an integration of both multiplex PCR and microarray on a Lab-on-Chip platform (VereChip™). It was specifically developed for the qualitative detection and differentiation of Escherichia coli (E. coli) O157:H7, E. coli O26, E. coli O45, E. coli O103, E. coli O111, E. coli O121, E. coli O145, STEC virulence factors (stx1A, stx2A, eae), and Salmonella spp. in a single test using raw beef trim samples.
VereBeef Press Release Final (Singapore)
Veredus Laboratories Pte Ltd is pleased to announce its acquisition by SEKISUI CHEMICAL CO., LTD1.
Founded in 2003, Veredus Laboratories Pte Ltd (hereinafter, “Veredus”) specializes in the development, manufacturing and marketing of innovative multiplexed molecular solutions in the clinical, specialty, and custom testing markets based on STMicroelectronics’ Lab-on-Chip platform. The Lab-on-Chip platform, also known as the VerePLEX™ Biosystem, combines Micro-Electro Mechanical Systems (MEMS) with micro-fluidics to integrate multiplexed DNA amplification with microarray detection for rapid, cost-effective, and accurate analysis of biological materials.
With this acquisition, Veredus will continue to carry its own product line and also welcome the medical products from SEKISUI MEDICAL CO., LTD., a company which is 100% subsidiary of SEKISUI CHEMICAL CO., LTD.
Dr Rosemary Tan will continue to lead Veredus as its Chief Executive Officer, and Veredus remains fully committed in bringing innovative technologies and quality products to our customers.
1Refer to Official Press Release by SEKISUI CHEMICAL CO., LTD, dated 3rd April, 2018
VereFever™ is able to detect, differentiate and identify 7 different major tropical diseases from a single blood sample, including Malaria, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis and Zika by using the STMicroelectronics proprietary Lab-on-Chip platform that integrates two powerful molecular biological applications, Polymerase Chain Reaction (PCR) and a microarray.
The Agri-Food and Veterinary Authority of Singapore (AVA) and Veredus Laboratories has jointly launched VereVet™, a portable Lab-on-Chip application that is able to detect, differentiate and identify nine major poultry infectious disease agents from one sample in one single test.